Expression of mesenchymal–epithelial transition factor in estrogen receptor-negative breast carcinoma

2022

Journal of the Arab Society for Medical Research, Vol 17, Iss 1, Pp 59-67 (2022)

Background/aim Breast carcinoma is a worldwide, heterogeneous disease that affects even the young patient population. The receptor tyrosine kinase mesenchymal–epithelial transition factor (c-Met) is suggested to be associated with reduced survival in cases of breast cancer. Few studies have specifically addressed the association between the c-Met and molecular subtype of breast cancer. This study aimed to evaluate the c-Met expression in estrogen receptor (ER)-negative breast cancers with different subtypes and its relation to the standard prognostic indicators. Patients and methods We examined the expression of c-Met in triple-negative and human epidermal growth factor receptor 2 enriched (i.e. ER-negative) breast cancers. Sixty formalin-fixed paraffin-embedded breast cancer surgical specimens were studied by immunohistochemistry. Prognostic indicators were analyzed with Cox models adjusted for clinical and pathological factors. Results Sixty-nine percent of cases were positive for Met. The reported mean Remmele score was 7.80±4.32. A significant positive correlation was observed between the tumor type, nodal status, multicentricity, and ductal carcinoma in situ (P

article

English

Wolters Kluwer Medknow Publications, 2022.

breast cancer, mesenchymal–epithelial transition factor receptor, targeted therapy, triple-negative breast cancer, Medicine